logo

For the Inventor, By the Inventor

Utrecht, Netherlands

Hilma Van Der Horst

This inventor holds 6 USPTO granted patents and 5 published patent applications. Top assignee: Genmab Holding B.v.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hilma Van Der Horst. Retrieved from https://idiyas.com/inventor/hilma-van-der-horst

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 100.0

Average Co-Inventor Count = 11.4

ph-index = 3

Forward Citations = 16(Granted Patents)


Company Filing History:

goldMedal6 out of 6 
 
Genmab Holding B.v.
 patents

Years Active: 2021-2026

Loading Chart...
6 patents (USPTO):Explore Patents
1. 12577316 - METHODS OF USE OF ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES (2026-03-17),
2. 12448459 - Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof (2025-10-21),
3. 12275797 - Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof (2025-04-14),
4. 11512137 - Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof (2022-11-29),
5. 11396553 - Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof (2022-07-26),
6. 11034772 - Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof (2021-06-15),

Title: Hilma Van Der Horst: Innovator in Antibody Therapeutics

Introduction

Hilma Van Der Horst is a prominent inventor based in Utrecht, Netherlands. She has made significant contributions to the field of antibody therapeutics, particularly in the development of bispecific antibodies. With a total of five patents to her name, her work focuses on innovative solutions for treating cancer and other diseases.

Latest Patents

Hilma's latest patents include groundbreaking inventions such as bispecific anti-CD37 antibodies and monoclonal anti-CD37 antibodies. These antibodies are designed to bind to different epitopes of the human CD37 antigen, enhancing Fc-Fc interactions upon binding to CD37 on the cell surface. This innovation also encompasses the parental antibodies from which the bispecific antibody molecules are derived. Additionally, her patents cover pharmaceutical compositions containing these molecules and their application in cancer treatment. Another notable invention involves anti-CD37 antibodies with Fc-Fc interaction enhancing substitutions, used in combination with anti-CD20 antibodies for therapeutic purposes. These compositions are particularly relevant in the treatment of cancer and other diseases.

Career Highlights

Hilma Van Der Horst is currently associated with Genmab Holding B.V., a leading biotechnology company specializing in the development of differentiated antibody therapeutics. Her work at Genmab has positioned her as a key player in the advancement of innovative cancer treatments.

Collaborations

Hilma collaborates with talented professionals in her field, including Simone Oostindie and Frank Beurskens. These collaborations enhance the research and development efforts at Genmab, contributing to the success of their innovative projects.

Conclusion

Hilma Van Der Horst's contributions to the field of antibody therapeutics are noteworthy and impactful. Her innovative patents and collaborations continue to pave the way for advancements in cancer treatment and other medical applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…